Next to Lead
Gilead Sciences moves at a pace rarely seen in pharma, delivering breakthrough COVID-19 antivirals and HIV preventatives in record time. Yet, in an industry facing a massive trust deficit, speed isn’t always enough. In this episode of Next to Lead, Johanna Mercier, Gilead’s Chief Commercial & Corporate Affairs Officer, joins Fortune’s Leadership Editor Ruth Umoh to discuss how the company is rewriting its narrative and balancing its patients with its shareholders. 00:00 Intro 01:05 Mercier’s role at Gilead 03:05 Work-life balance and managing energy 05:10 Mercier’s biology and business background 06:02 Personal motivation and prioritizing patients 08:10 Balancing profits with patients 09:04 Public trust 11:03 Resilience following failure 13:02 Drug pricing agreements with the federal government 14:33 Growth engines for Gilead 15:24 Gilead’s billion-dollar acquisition strategy 17:24 Gilead’s COVID-19 and SARS pivot 18:07 Gilead’s AI strategy 21:34 Responsible AI use 22:10 AI-powered predictive analytics 23:07 Mercier’s leadership strategy 24:24 Ending HIV 25:30 Rapid-fire questions 30:45 Outro Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]
18 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Next to Lead!